SOUTHERN JOURNAL OF SCIENCES

Introdução: A entrevista com Élcio Gerônimo de Oliveira, conduzida pelo repórter Luis, apresenta a trajetória profissional de um pesquisador brasileiro com experiência na Força Aérea Brasileira e no meio acadêmico, com foco em sistemas espaciais e veículos hipersônicos. Objetivos: Documentar a carreira e contribuições de Élcio para o desenvolvimento aeroespacial brasileiro, destacando sua transição da carreira militar para a acadêmica e sua participação em projetos estratégicos, especialmente o projeto 14X. Métodos: A entrevista foi estruturada em blocos temáticos, abordando a carreira militar, a experiência acadêmica e, com maior detalhamento, o envolvimento no projeto do veículo hipersônico 14X. Foram realizadas perguntas abertas, permitindo ao entrevistado compartilhar sua experiência e conhecimento técnico. Resultados: Élcio descreveu sua progressão na Força Aérea Brasileira, desde pesquisador até vice-chefe da Diretoria de Espaço, destacando o desenvolvimento de veículos lançadores, sistemas de navegação inercial e o projeto SARA. Relatou sua transição para a carreira acadêmica, incluindo sua experiência como professor na Universidade de Luleå, na Suécia. Élcio detalhou sua coordenação no projeto 14X, um veículo hipersônico que alcançou Mach 7, com perspectivas de atingir Mach 10. Discussão: A entrevista revela a importância da cooperação internacional e da transferência de tecnologia, exemplificada pela doação do primeiro laboratório de hipersônica do Brasil. Evidencia também os desafios técnicos na construção de veículos hipersônicos e o potencial dessas tecnologias para aplicações militares e civis. Conclusão: A carreira de Élcio Gerônimo de Oliveira exemplifica a contribuição brasileira para pesquisa aeroespacial avançada, demonstrando a capacidade nacional de desenvolver tecnologias estratégicas como veículos hipersônicos, apesar das limitações de recursos, e apontando possibilidades futuras para o transporte e exploração espacial.

Background: The Epstein-Barr virus (EBV) has recently been identified in human breast cancer globally, potentially contributing to the initiation and progression of this malignancy, as well as gastric cancer, nasopharyngeal carcinoma, and bladder cancer. It has been newly associated with breast cancer. Globally, breast cancer affects more women than any other type of cancer. In Iraq, the prevalence of breast cancer is comparable. Aims: The study examined Iraqi women diagnosed with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) to detect Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) and encoded RNA (EBER). Methods: A total of 50 formalin-fixed paraffin-embedded tissues from invasive ductal carcinoma (IDC) (92%) and invasive lobular carcinoma (ILC) (8%) biopsy samples constituted the case group, while 30 formalin-fixed paraffin-embedded tissues from non-cancerous breast tissue served as the control group. The presence of Epstein-Barr virus protein (EBER) in breast tissue was assessed using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) methods. Results: EBER RNA signals were found in 31 (62%). EBER RNA signals were seen in 3 (10%) control group participants. Significant differences (P<0.04) were seen in EBV EBER RNA positive signals among study groups. Immunohistochemistry showed nuclear brown staining in 34 (68%) breast cancer patients. Control group: 3 (10%). Discussion: The research identified a statistically significant correlation between EBV positivity and breast cancer among Iraqi women, especially concerning invasive ductal carcinoma. The results corroborate previous reports of elevated EBV levels in malignant breast tissues relative to controls. Although detection approaches such as CISH and IHC provide complementary insights, additional studies are needed. Conclusions: The study concludes that EBNA-1 and EBV EBER RNA were overexpressed in our population group.

Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological malignancy predominantly affecting individuals under 20 years of age. Traditional chemotherapy, such as clofarabine, has shown efficacy; however, novel immunotherapeutic strategies like tisagenlecleucel (Kymriah®) have significantly altered the treatment paradigm. Aim: This study aimed to perform a comparative analysis of tisagenlecleucel, a CAR-T cell therapy, and clofarabine, a second-generation purine nucleoside analog, evaluating their mechanisms of action, therapeutic benefits, limitations, and clinical applicability across diverse patient populations. Methods: A systematic comparative evaluation was conducted, encompassing pharmacological characteristics, mechanisms of action, treatment protocols, efficacy, safety profiles, and clinical indications of both agents. The analysis considered pharmacokinetic and pharmacodynamic data and included patient demographic variables. Results: Tisagenlecleucel demonstrated high efficacy in refractory B-cell ALL, with durable responses and a blood half-life of 128 days, but with notable immune-related adverse effects such as cytokine release syndrome. Clofarabine, effective across a broader patient population, acts via multiple antitumor mechanisms but carries significant toxicity risks, including infection and sepsis. Discussion: The therapies present distinct clinical profiles: tisagenlecleucel offers targeted immunotherapy with high specificity but requires specialized infrastructure and management of immune toxicities. Clofarabine is more widely accessible and applicable, but is associated with conventional chemotherapy-related side effects. Treatment accessibility and cost differ markedly between the two. Conclusions: Therapy selection should be personalized based on patient-specific factors and institutional resources. Tisagenlecleucel is ideal for pediatric and young adult patients with relapsed/refractory B-cell ALL in CAR-T-capable centers, while clofarabine remains a viable option for broader ALL populations, particularly when genetic therapies are not feasible. Further research is needed to optimize therapeutic strategies and improve access to advanced treatments.